Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spotting Switching Opportunities in Ophthalmology

This article was originally published in Start Up

Executive Summary

The buzz around ophthalmology is trickling down to company creation. French start-up Fovea will buy in and build compounds tackling the root causes of retinal diseases.

Related Content

Glaucoma's Changing Of The Guard
Start-Up News March 2007
Ophthalmology's Next Frontier
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
The A-List: 2005's Trend-Shaping Series A Financings
OSI Buys Eyetech, Market Rubs Eyes
OSI Buys Eyetech, Market Rubs Eyes
Alimera Sciences Inc.
Devices for Age-Related Macular Degeneration
RNAi Enters the Clinic for Macular Degeneration


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts